Figure 2.
Effect of AZA treatment in the transcriptome of CD4+T cells from patients with HR-MDS. (A-B) Volcano plots depicting the differentially expressed genes in CD4+ T cells after 6 cycles of treatment compared with pretreatment in patients with complete response to treatment (CR, n = 4) (A) and in patients who failed AZA (n = 4) (B). The distribution of the FDR values (−log[FDR]) and the fold changes (log2 fold change) are shown. Significance level was adjusted to FDR <0.2. (C) Venn diagram depicting the number of differentially expressed genes after AZA therapy compared with pretreatment in patients with CR or failure to AZA. (D) Gene set enrichment analysis for genes associated with the inflammatory response, IL-6_JAK_STAT3 and IL-2_STAT5 signaling in patients with CR, and in patients that failed AZA (E). (F) Real-time quantitative polymerase chain reaction analysis of the STAT3 target gene BCL3 in isolated peripheral blood CD4+ T cells before and after 6 cycles of AZA (cy6). NES, normalized enrichment score.

Effect of AZA treatment in the transcriptome of CD4+T cells from patients with HR-MDS. (A-B) Volcano plots depicting the differentially expressed genes in CD4+ T cells after 6 cycles of treatment compared with pretreatment in patients with complete response to treatment (CR, n = 4) (A) and in patients who failed AZA (n = 4) (B). The distribution of the FDR values (−log[FDR]) and the fold changes (log2 fold change) are shown. Significance level was adjusted to FDR <0.2. (C) Venn diagram depicting the number of differentially expressed genes after AZA therapy compared with pretreatment in patients with CR or failure to AZA. (D) Gene set enrichment analysis for genes associated with the inflammatory response, IL-6_JAK_STAT3 and IL-2_STAT5 signaling in patients with CR, and in patients that failed AZA (E). (F) Real-time quantitative polymerase chain reaction analysis of the STAT3 target gene BCL3 in isolated peripheral blood CD4+ T cells before and after 6 cycles of AZA (cy6). NES, normalized enrichment score.

Close Modal

or Create an Account

Close Modal
Close Modal